These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21269761)

  • 1. Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis.
    Nadjar Y; Coutelas E; Prouteau P; Panzer F; Paquet D; Saint-Val C; Créange A
    Clin Neurol Neurosurg; 2011 May; 113(4):316-22. PubMed ID: 21269761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis.
    Fragoso YD; Frota ER; Lopes JS; Noal JS; Giacomo MC; Gomes S; Gonçalves MV; da Gama PD; Finkelsztejn A
    Clin Neuropharmacol; 2010; 33(6):312-6. PubMed ID: 21079457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H; Hohlfeld R
    Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
    Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
    Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of chronotype and timing of interferon injection with severity of IFNβ-induced flu-like syndrome in Multiple sclerosis (MS) patients.
    Maghbooli M; Karami M; Mohammadi V
    J Clin Neurosci; 2024 Oct; 128():110811. PubMed ID: 39197331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral therapy for multiple sclerosis!].
    de Seze J
    Rev Neurol (Paris); 2010 Apr; 166(4):363-4. PubMed ID: 20385331
    [No Abstract]   [Full Text] [Related]  

  • 8. Behind the paper: saved from the drain.
    Dolgin E
    Nat Med; 2010 Apr; 16(4):378. PubMed ID: 20376044
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.
    Martínez-Cáceres EM; Río J; Barrau M; Durán I; Borrás C; Tintoré M; Montalban X
    Ann Neurol; 1998 Oct; 44(4):682-5. PubMed ID: 9778268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC
    Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous reactions following subcutaneous beta-interferon-1b injection.
    Ohata U; Hara H; Yoshitake M; Terui T
    J Dermatol; 2010 Feb; 37(2):179-81. PubMed ID: 20175855
    [No Abstract]   [Full Text] [Related]  

  • 14. Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta?
    Montalban X; Durán I; Río J; Sáez-Torres I; Tintoré M; Martínez-Cáceres EM
    J Neurol; 2000 Apr; 247(4):259-62. PubMed ID: 10836616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM; Peppler R; VanderBrug Medendorp S; Lehmann P; Alam J
    Ann Neurol; 1996 Oct; 40(4):618-27. PubMed ID: 8871582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.
    Banwell B; Reder AT; Krupp L; Tenembaum S; Eraksoy M; Alexey B; Pohl D; Freedman M; Schelensky L; Antonijevic I
    Neurology; 2006 Feb; 66(4):472-6. PubMed ID: 16505297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon-beta therapy and neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2009 Jul; 212(1-2):132-41. PubMed ID: 19443048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
    Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
    Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of multiple sclerosis: the PROOF trial.
    Boster A; Racke MK
    Expert Opin Pharmacother; 2009 Jun; 10(8):1235-7. PubMed ID: 19463066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.